Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Angiogenesis inhibitors (vascular endothelial growth factor/vascular signaling pathway inhibitors) have advanced cancer treatment.
• Cardiovascular toxicities, including hypertension and heart failure, are significant limiting factors.
• Managing these toxicities is crucial for maintaining oncological treatment efficacy.

Purpose of the Study:

• To present a team-based strategy for managing hypertension induced by angiogenesis inhibitors.
• To provide recommendations for monitoring and selecting antihypertensive agents in cancer patients.

Main Methods:

• Literature review and expert consensus on managing angiogenesis inhibitor-related cardiovascular toxicities.
• Development of a collaborative, multidisciplinary care model.
• Guideline recommendations for antihypertensive therapy selection and monitoring.

Main Results:

• Hypertension is a common toxicity of angiogenesis inhibitors, requiring proactive management.
• A structured, team-based approach can effectively manage these cardiovascular complications.
• Evidence-based recommendations for antihypertensive selection are provided.

Conclusions:

• Effective management of angiogenesis inhibitor-induced cardiovascular toxicities is essential for optimal cancer care.
• A collaborative approach involving oncologists and cardiologists improves patient outcomes.
• Careful monitoring and appropriate antihypertensive selection are key to balancing treatment benefits and risks.